跳至主要内容
临床试验/IRCT2017071435080N1
IRCT2017071435080N1已完成1 期

The evaluaation of Nano-micelle curcumin efficacy in patients whit mild to moderate ulcerative culities

EXIR nano sina0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
All

入选标准

  • It’s a randomized double blind controlled trial in patients with mild to moderate ulcerative colitis which is under treatment with maximum dose of mesalamine. Patients aged between 18-70 years old with UC, which has been approved by endoscopy, will be enrolled. Mild to moderate active UC based on simple clinical colitisactivity index (SCCAI) score” will be defined as <5 and <12 score, respectively. subjects with history of current or in past 12 weeks use of steroids, taking anti-TNF or cyclosporine, has Hgb<10 mg/dl or hematologic abnormalities including leukopenia, thrombocytopenia, those with impaired renal, coagulation or liver tests, subjects with positive C diff infection, pregnant patients, presence of active sepsis and nurses will be excluded from the study.

排除标准

  • 未提供

研究者

发起方
EXIR nano sina

相似试验